Login
$IONS
$28.02 +$0.01 (0.04%) After hours

$IONS SEC Filings

Filed On Filing
13 Nov 2026 Form 4: Hayden Michael R, Director

Bought 5,000 shares ($148K)

09 Nov 2026 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
09 Nov 2026 8-K: Results of Operations and Financial Condition

– ZANVASTROTM (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline –

23 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

21 Oct 2026 8-K: Regulation FD Disclosure; Other Events

– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care –

19 Oct 2026 Form 4: Devers Shannon L., EVP, Chief Human Resources Ofc

Received 2,820 shares by exercise or conversion · Sold 1,357 shares ($59.1K)

19 Oct 2026 Form 4: Swayze Eric, EVP Research

Received 125 shares by exercise or conversion · Sold 53 shares ($2.31K)

16 Oct 2026 144
23 Sep 2026 8-K: Regulation FD Disclosure; Other Events

– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –

04 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

04 Sep 2026 8-K: Regulation FD Disclosure; Other Events

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

02 Sep 2026 Form 4: Bennett C Frank, EVP, Chief Scientific Officer

Acquired 110 shares (Other Transaction) ($5.64K)

02 Sep 2026 Form 4: O'neil Patrick R., EVP CLO & General Counsel

Acquired 63 shares (Other Transaction) ($3.23K)

02 Sep 2026 Form 4: Monia Brett P, Director

Acquired 98 shares (Other Transaction) ($5.03K)

02 Sep 2026 Form 4: Birchler Brian, EVP, Corp and Development Ops

Acquired 58 shares (Other Transaction) ($2.98K)

31 Jul 2026 Form 4: Hayden Michael R, Director

Bought 15,000 shares ($801K) · Bought 5,000 shares ($258K)

31 Jul 2026 S-8
29 Jul 2026 IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026
29 Jul 2026 8-K: Results of Operations and Financial Condition

- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population –

17 Jul 2026 Form 4: Reikes Peter N, Director

Granted 3,399 Restricted Stock Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support